← Leaderboards
Kevin A Cassady
University Of Alabama At Birmingham
$2,896,264
Attributed
$3,736,381
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2018–23$2.5M$1.9M$1.3M$625K$0
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$4,276,529 · 5
By mechanism
U54$2,369,037 · 3
R01$1,680,234 · 1
K08$227,258 · 1
Top collaborators
- James M Markert3 shared
- Timothy P Cripe1 shared
- John M Maris1 shared
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- David T Curiel$31,690,411
- James M Markert$5,310,460
- Ralph R Weichselbaum$16,065,057
- Louis B Nabors$6,698,272
- M R Chambers$2,636,972
Others in their field
Top investigators on “Immune Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,695,345
- Barton F Haynes · Duke University$456,664,915
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$309,708,725
- Peter B. Gilbert · Fred Hutchinson Cancer Center$192,329,665
Research focus
Immune ResponseVirusMalignant NeoplasmsImmuneT-LymphocyteBaseDesignGliomaViralTumorRecruitCytokineEngineeringOncolytic Herpes Simplex VirusResponseImmunologic MonitoringCellsAntitumor ResponseMalignant GliomaChemokineInfectionMediatingAdaptive Immune ResponseClinical Trials
Grant awards (8)
Oncolytic virus bispecific gene delivery for high grade gliomas$366,900
U54 · FY2023 · CA
Engaging and Enhancing Neuroblastoma Immune Targeting$173,248
U54 · FY2021 · CA
Oncolytic Immunotherapy using Chimeric HSV C134: A Phase I Trial and Establishment of Response Indicators in Recurrent Glioma Patients$551,600
R01 · FY2020 · CA
Project 3: Breaking tolerance and improving the immune mediated response though oncolytic virus based therapy$1,828,889
U54 · FY2019 · CA · contact PI
Oncolytic Immunotherapy using Chimeric HSV C134: A Phase I Trial and Establishment of Response Indicators in Recurrent Glioma Patients$542,479
R01 · FY2019 · CA
Oncolytic Immunotherapy using Chimeric HSV C134: A Phase I Trial and Establishment of Response Indicators in Recurrent Glioma Patients$586,155
R01 · FY2018 · CA
HSV US11 MEDIATED EVASION OF HOST SHUTOFF$114,198
K08 · FY2001 · AI
HSV US11 MEDIATED EVASION OF HOST SHUTOFF$113,060
K08 · FY2000 · AI